Jacobs Levy Equity Management
INZY

Jacobs Levy Equity Management’s Inozyme Pharma INZY Stock Holding History

Jacobs Levy Equity Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-129,749
Closed -$359K – 1138
2024
Q4 		$359K Buy
+129,749
New +$493K ﹤0.01% 854
2022
Q1 		– Sell
-88,921
Closed -$606K – 1031
2021
Q4 		$606K Buy
88,921
+67,884
+323% +$586K ﹤0.01% 813
2021
Q3 		$244K Buy
+21,037
New +$328K ﹤0.01% 959

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's INZY Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of Inozyme Pharma (INZY) in Q1 2025, closing a stake of 129,749 shares — an estimated $359K sold.

Jacobs Levy Equity Management first reported a position in INZY in Q3 2021 and held it in 3 quarters. The position peaked at $606K in Q4 2021. 97 funds tracked by Wall St. Rank hold INZY as of Q1 2025.

  • Jacobs Levy Equity Management reported no remaining Inozyme Pharma position as of Q1 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 129,749 Inozyme Pharma shares in Q1 2025, an estimated $359K.
  • Jacobs Levy Equity Management first reported a position in Inozyme Pharma in Q3 2021 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Inozyme Pharma position peaked at $606K in Q4 2021.
  • 97 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.